High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy
Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates fav...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2432059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850060226127986688 |
|---|---|
| author | Lucillia Bezu Guido Kroemer |
| author_facet | Lucillia Bezu Guido Kroemer |
| author_sort | Lucillia Bezu |
| collection | DOAJ |
| description | Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab. |
| format | Article |
| id | doaj-art-cd36160065ac45ac8fb6223beeaf218d |
| institution | DOAJ |
| issn | 2162-402X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-cd36160065ac45ac8fb6223beeaf218d2025-08-20T02:50:38ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2432059High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapyLucillia Bezu0Guido Kroemer1Equipe labellisée par La Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Paris, FranceEquipe labellisée par La Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Paris, FranceFew clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2432059BiomarkercancerchemotherapyimmunotherapyPD-1 blockade |
| spellingShingle | Lucillia Bezu Guido Kroemer High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy OncoImmunology Biomarker cancer chemotherapy immunotherapy PD-1 blockade |
| title | High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy |
| title_full | High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy |
| title_fullStr | High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy |
| title_full_unstemmed | High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy |
| title_short | High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy |
| title_sort | high circulating hmgb1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy |
| topic | Biomarker cancer chemotherapy immunotherapy PD-1 blockade |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2432059 |
| work_keys_str_mv | AT lucilliabezu highcirculatinghmgb1indicatesgoodprognosisinpatientswithadvancedleiomyosarcomaunderchemoimmunotherapy AT guidokroemer highcirculatinghmgb1indicatesgoodprognosisinpatientswithadvancedleiomyosarcomaunderchemoimmunotherapy |